Predictors of Clinical Response and Remission at One year among a Multicenter Cohort of Patients with Inflammatory Bowel Disease Treated with Vedolizumab

BACKGROUND: Vedolizumab (VDZ) has demonstrated long term efficacy in Crohn’s disease (CD) and ulcerative colitis (UC) in phase III trials. AIMS: Our aim was to evaluate the efficacy of VDZ at week 54 in inflammatory bowel disease (IBD) in a multicenter cohort of patients. METHODS: Adult patients com...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Dig Dis Sci
Autori principali: Allegretti, Jessica R., Barnes, Edward L., Stevens, Betsey, Storm, Margaret, Ananthakrishnan, Ashwin, Yajnik, Vijay, Korzenik, Joshua
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2017
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5661939/
https://ncbi.nlm.nih.gov/pubmed/28357697
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10620-017-4549-3
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi